{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:33:08Z","timestamp":1786120388921,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/ico.0b013e31822481c2","type":"journal-article","created":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T09:13:04Z","timestamp":1330506784000},"page":"649-654","source":"Crossref","is-referenced-by-count":21,"title":["Topical Calcineurin Inhibitors in the Treatment of Steroid-Dependent Atopic Keratoconjunctivitis"],"prefix":"10.1097","volume":"31","author":[{"given":"Jonathan H.","family":"Tzu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan Asli","family":"Utine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen Karamursel","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210204","first-page":"265","article-title":"Atopic keratoconjunctivitis.","volume":"50","author":"Hogan","year":"1952","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R2-11-20210204","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0161-6420(91)32154-7","article-title":"Immunopathology of atopic keratoconjunctivitis.","volume":"98","author":"Foster","year":"1991","journal-title":"Ophthalmology"},{"key":"R3-11-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0161-6420(90)32477-6","article-title":"Atopic keratoconjunctivitis.","volume":"97","author":"Foster","year":"1990","journal-title":"Ophthalmology"},{"key":"R4-11-20210204","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0161-6420(98)94017-9","article-title":"Long-term follow-up of patients with atopic keratoconjunctivitis.","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"key":"R5-11-20210204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0039-6257(86)90035-4","article-title":"Cyclosporine: immunology, pharmacology and therapeutic uses.","volume":"31","author":"Nussenblatt","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"R6-11-20210204","first-page":"2686","article-title":". Topical cyclosporine inhibits mast cell-mediated conjunctivitis.","volume":"37","author":"Whitcup","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-11-20210204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2008-1045885","article-title":"Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin Aa retrospective study of 18 patients in German.","volume":"201","author":"Reinhard","year":"1992","journal-title":"Klin Monbl Augenheilkd"},{"key":"R8-11-20210204","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0161-6420(97)30144-4","article-title":". Systemic cyclosporine A in severe atopic keratoconjunctivitis.","volume":"104","author":"Hoang-Xuan","year":"1997","journal-title":"Ophthalmology"},{"key":"R9-11-20210204","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":". A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis.","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"issue":"pt B","key":"R10-11-20210204","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/978-1-4615-0717-8_114","article-title":". Topical cyclosporine A (2) eyedrops in the therapy of atopic keratoconjunctivitis and keratoconjunctivitis vernalis.","volume":"506","author":"Tomida","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"R11-11-20210204","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":". A randomized trial of topical cyclosporin 0.05 in topical steroid-resistant atopic keratoconjunctivitis.","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"R12-11-20210204","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","article-title":"Management of severe allergic conjunctivitis with topical cyclosporin a 0.05 eyedrops.","volume":"26","author":"Ozcan","year":"2007","journal-title":"Cornea"},{"key":"R13-11-20210204","first-page":"191","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects.","volume":"23","author":"Rico","year":"2002","journal-title":"Allergy Asthma Proc"},{"key":"R14-11-20210204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3129\/i09-117","article-title":"0.05 cyclosporine a for treatment of chronic severe ocular surface disease in French.","volume":"44","author":"Nochez","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"R15-11-20210204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":". A large prospective observational study of novel cyclosporine 0.1 aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.","volume":"25","author":"Ebihara","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R16-11-20210204","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/ICO.0b013e318172fbb1","article-title":". Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis.","volume":"27","author":"Anzaar","year":"2008","journal-title":"Cornea"},{"key":"R17-11-20210204","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":". Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R18-11-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004397-199303340-00005","article-title":"Clinical use of cyclosporine in ocular disease.","volume":"33","author":"de Smet","year":"1993","journal-title":"Int Ophthalmol Clin"},{"key":"R19-11-20210204","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":". Phase III safety evaluation of cyclosporine 0.1 ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"R20-11-20210204","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ajo.2008.12.007","article-title":"Occult thyroid eye disease in patients presenting with dry eye symptoms.","volume":"147","author":"Gupta","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R21-11-20210204","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","article-title":"High-frequency topical cyclosporine 0.05 in the treatment of severe dry eye refractory to twice-daily regimen.","volume":"28","author":"Dastjerdi","year":"2009","journal-title":"Cornea"},{"key":"R22-11-20210204","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":". Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"R23-11-20210204","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1358\/dot.2006.42.7.1003316","article-title":"Tacrolimus: focusing on atopic dermatitis.","volume":"42","author":"Carroll","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"R24-11-20210204","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":". Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids.","volume":"23","author":"Zribi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201206000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:42:55Z","timestamp":1786048975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201206000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31822481c2","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}